ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Sun Pharma Inks Global Licensing Deal with Philogen for Anti-Cancer Drug Fibromun

NextEdge Admin

01 Oct 2024

1 min 57 sec

Sun Pharmaceutical Industries announced a global licensing agreement with Italian-Swiss firm Philogen for Fibromun, an innovative anti-cancer immunotherapy. Under the agreement, Sun Pharma will hold exclusive worldwide commercialisation rights for Fibromun, which is being tested in pivotal registration trials for treating soft tissue sarcoma and glioblastoma. Philogen will continue conducting clinical trials, seek marketing authorization from regulatory bodies, and handle commercial manufacturing, while Sun Pharma will manage commercialisation efforts.

The companies will share post-commercialisation profits, with Philogen receiving 45% and Sun Pharma 55%. While specific financial terms were not disclosed, Sun Pharma's Chairman and Managing Director, Dilip Shanghvi, expressed optimism about Fibromun's development, highlighting its potential as a key treatment option for cancers with unmet medical needs. He emphasized that this partnership aligns with Sun Pharma's current oncology portfolio, which focuses on skin cancers, and expressed eagerness to offer this treatment worldwide.

Philogen’s CEO and CSO, Dario Neri, noted that Fibromun has shown promising therapeutic results, particularly in glioblastoma patients, by inducing long-lasting anti-tumor responses. This new collaboration builds on a previous agreement between the two companies, where Sun Pharma secured rights to commercialize Philogen's specialty product Nidlegy in Europe, Australia, and New Zealand.